OK Biotech Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de OK Biotech.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	22.7%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

OK Biotech's (TWSE:4155) Shareholders Have More To Worry About Than Lackluster Earnings

Aug 20

OK Biotech Co., Ltd. (TPE:4155) Investors Should Think About This Before Buying It For Its Dividend

Apr 26

Is OK Biotech Co., Ltd.'s (TPE:4155) Recent Price Movement Underpinned By Its Weak Fundamentals?

Feb 15

A Look At OK Biotech's (TPE:4155) Share Price Returns

Jan 31

We Wouldn't Rely On OK Biotech's (TPE:4155) Statutory Earnings As A Guide

Jan 17

Consider This Before Buying OK Biotech Co., Ltd. (TPE:4155) For The 5.4% Dividend

Jan 03

Estimating The Intrinsic Value Of OK Biotech Co., Ltd. (TPE:4155)

Dec 21

Here's Why OK Biotech (TPE:4155) Can Manage Its Debt Responsibly

Dec 08

Should You Be Impressed By OK Biotech's (TPE:4155) Returns on Capital?

Nov 23

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como OK Biotech no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

TWSE:4155 - Estimaciones futuras de los analistas y datos financieros pasados (TWD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2024	1,343	48	-32	179	N/A
3/31/2024	1,223	21	-152	19	N/A
12/31/2023	1,192	3	-434	3	N/A
9/30/2023	1,238	29	-227	144	N/A
6/30/2023	1,271	74	-390	196	N/A
3/31/2023	1,387	113	-359	236	N/A
12/31/2022	1,484	143	-54	241	N/A
9/30/2022	1,519	147	-72	210	N/A
6/30/2022	1,520	116	45	129	N/A
3/31/2022	1,385	62	-14	63	N/A
12/31/2021	1,263	43	-65	22	N/A
9/30/2021	1,358	81	-124	27	N/A
6/30/2021	1,391	92	-44	43	N/A
3/31/2021	1,410	113	8	108	N/A
12/31/2020	1,484	130	68	148	N/A
9/30/2020	1,407	127	-33	45	N/A
6/30/2020	1,356	139	-11	112	N/A
3/31/2020	1,330	143	-117	-7	N/A
12/31/2019	1,241	126	-32	82	N/A
9/30/2019	1,169	133	36	87	N/A
6/30/2019	1,145	144	-48	0	N/A
3/31/2019	1,107	148	65	90	N/A
12/31/2018	1,120	161	77	105	N/A
9/30/2018	1,075	148	57	107	N/A
6/30/2018	1,157	139	88	148	N/A
3/31/2018	1,239	143	N/A	153	N/A
12/31/2017	1,233	127	N/A	98	N/A
9/30/2017	1,281	116	N/A	123	N/A
6/30/2017	1,182	80	N/A	155	N/A
3/31/2017	1,092	74	N/A	149	N/A
12/31/2016	1,040	85	N/A	261	N/A
9/30/2016	964	97	N/A	253	N/A
6/30/2016	942	123	N/A	272	N/A
3/31/2016	894	122	N/A	338	N/A
12/31/2015	857	111	N/A	289	N/A
9/30/2015	758	97	N/A	N/A	N/A
6/30/2015	660	83	N/A	237	N/A
3/31/2015	647	77	N/A	102	N/A
12/31/2014	634	71	N/A	-34	N/A
9/30/2014	784	84	N/A	N/A	N/A
6/30/2014	934	96	N/A	-79	N/A
3/31/2014	1,004	117	N/A	4	N/A
12/31/2013	1,074	138	N/A	87	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de 4155 es superior a la tasa de ahorro (1.1%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de 4155 crezcan más rápidamente que el mercado TW

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de 4155 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de 4155 crezcan más rápidamente que el mercado de TW.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de 4155 crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 4155 se prevé que sea elevada dentro de 3 años.

OK Biotech Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

OK Biotech Co., Ltd. to Report Q3, 2024 Results on Nov 12, 2024

OK Biotech's (TWSE:4155) Shareholders Have More To Worry About Than Lackluster Earnings

Second quarter 2024 earnings released: EPS: NT$0.29 (vs NT$0.12 in 2Q 2023)

Dividend of NT$0.30 announced

Ok Biotech Co., Ltd. Announces Cash Dividend, Payable on September 27, 2024

OK Biotech Co., Ltd. to Report Q2, 2024 Results on Aug 09, 2024

OK Biotech Co., Ltd. Announces Change of Directors

First quarter 2024 earnings released: EPS: NT$0.25 (vs NT$0.16 in 1Q 2023)

OK Biotech Co., Ltd. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: EPS: NT$0.02 (vs NT$1.37 in FY 2022)

OK Biotech Co., Ltd., Annual General Meeting, May 29, 2024

New minor risk - Profit margin trend

New minor risk - Market cap size

Upcoming dividend of NT$1.23 per share at 3.8% yield

Second quarter 2023 earnings released: EPS: NT$0.13 (vs NT$0.57 in 2Q 2022)

New major risk - Dividend sustainability

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: NT$1.51 (vs NT$0.46 in FY 2021)

Third quarter 2022 earnings released: EPS: NT$0.49 (vs NT$0.16 in 3Q 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: NT$0.57 (vs NT$0.002 loss in 2Q 2021)

Upcoming dividend of NT$1.00 per share

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Now 21% undervalued after recent price drop

Third quarter 2021 earnings released: EPS NT$0.16 (vs NT$0.30 in 3Q 2020)

Second quarter 2021 earnings released: NT$0.002 loss per share (vs NT$0.27 profit in 2Q 2020)

Upcoming dividend of NT$1.39 per share

First quarter 2021 earnings released: EPS NT$0.32 (vs NT$0.61 in 1Q 2020)

OK Biotech Co., Ltd. (TPE:4155) Investors Should Think About This Before Buying It For Its Dividend

Calculating The Fair Value Of OK Biotech Co., Ltd. (TPE:4155)

Full year 2020 earnings released: EPS NT$1.56 (vs NT$1.71 in FY 2019)

OK Biotech (TPE:4155) Has A Pretty Healthy Balance Sheet

OK Biotech Co., Ltd., Annual General Meeting, May 27, 2021

Has OK Biotech (TPE:4155) Got What It Takes To Become A Multi-Bagger?

Is OK Biotech Co., Ltd.'s (TPE:4155) Recent Price Movement Underpinned By Its Weak Fundamentals?

A Look At OK Biotech's (TPE:4155) Share Price Returns

We Wouldn't Rely On OK Biotech's (TPE:4155) Statutory Earnings As A Guide

New 90-day low: NT$26.45

Consider This Before Buying OK Biotech Co., Ltd. (TPE:4155) For The 5.4% Dividend

New 90-day low: NT$26.55

Estimating The Intrinsic Value Of OK Biotech Co., Ltd. (TPE:4155)

New 90-day low: NT$27.85

Here's Why OK Biotech (TPE:4155) Can Manage Its Debt Responsibly

Should You Be Impressed By OK Biotech's (TPE:4155) Returns on Capital?

Third quarter 2020 earnings released: EPS NT$0.30

Revenue and earnings miss expectations

New 90-day high: NT$31.70

New 90-day low - NT$26.05

First half earnings released

OK Biotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of TWD 34.268 million.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento